Sanjay Shankar, MD
Interventional Cardiology · Phoenix, AZNPI 1881893121
Payments from drug & device makers
Across 354 payments — averaging $33.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$3K
- Abiomed$1K
- Medtronic$813
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$769
- Boston Scientific$690
- Novartis$687
- plus $4K from 32 others
What the payments were for
- Travel & lodging$7967%
- Food & beverage$10,84591%
- Education$2562%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 61 | $3,473 |
| Abiomed | 17 | $1,193 |
| Medtronic(2 entities) | 11 | $813 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 26 | $769 |
| Boston Scientific | 18 | $690 |
| Novartis | 37 | $687 |
| Merck | 27 | $580 |
| Boehringer Ingelheim | 20 | $482 |
| Johnson & Johnson | 19 | $302 |
| Pfizer | 14 | $248 |
| Actelion Pharmaceuticals US, Inc. | 6 | $239 |
| Amgen | 14 | $234 |
| AstraZeneca | 13 | $213 |
| Cleerly, Inc. | 2 | $166 |
| Atricure, Inc. | 1 | $154 |
| Bardy Diagnostics, Inc. | 10 | $150 |
| Bard Peripheral Vascular, Inc. | 1 | $128 |
| Esperion Therapeutics, Inc. | 4 | $123 |
| Heartflow, Inc. | 1 | $118 |
| Edwards Lifesciences | 5 | $108 |
| Biosense Webster, Inc. | 3 | $102 |
| Bridgebio Pharma, Inc. | 3 | $99 |
| Sanofi-aventis U.S. LLC | 6 | $95 |
| Daiichi Sankyo Inc. | 3 | $80 |
| Chiesi USA, Inc. | 5 | $80 |
| Shockwave Medical, Inc | 1 | $78 |
| E.r. Squibb & Sons, L.L.C. | 5 | $71 |
| Inspire Medical Systems, Inc. | 3 | $71 |
| Alnylam Pharmaceuticals Inc. | 3 | $59 |
| Novo Nordisk | 2 | $48 |
| ZOLL Respicardia, Inc. | 2 | $46 |
| Philips North America LLC | 2 | $45 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $33 |
| Amarin Pharma, Inc. | 2 | $30 |
| Cook Medical LLC | 2 | $29 |
| Kestra Medical Technology Services, Inc. | 1 | $23 |
| Astellas Pharma US Inc | 1 | $23 |
| Preventice Services, LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Impella$738
- Fortify Assura$721
- Mitra Clip system$361
- CardioMEMS HF System$330
- COREVALVE EVOLUT R$247
- GALLANT$189
- JOT DX$183
- MitraClip System$175
- MitraClip$163
- LifeVest$159
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$154
- Micra$140
- CoreValve Evolut$133
- Venclose Maven Catheter$128
- FFRct$118
- AZURE XT DR MRI SURESCAN$106
- GENERAL TACHY$105
- LUX-DX$103
- JARDIANCE$102
- Cleerly Ischemia$102
How this compares
$11,898 in reported general payments places this provider in the 45th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 183 | $245,353 |
| EntrestoSacubitril/Valsartan | 83 | $108,716 |
| JardianceEmpagliflozin | 91 | $96,405 |
| XareltoRivaroxaban | 70 | $77,833 |
| FarxigaDapagliflozin Propanediol | 30 | $32,523 |
| Repatha SureclickEvolocumab | 14 | $9,825 |
| BrilintaTicagrelor | 11 | $9,729 |
| Metoprolol Succinate | 396 | $4,453 |
| Atorvastatin Calcium | 279 | $3,034 |
| Ranolazine ErRanolazine | 13 | $2,202 |
| ClopidogrelClopidogrel Bisulfate | 117 | $1,563 |
| Rosuvastatin Calcium | 113 | $1,405 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 78 | $1,371 |
| Bumetanide | 32 | $1,283 |
| Carvedilol | 107 | $1,130 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $248 | $245,353183 claims |
| NovartisEntresto | $687 | $108,71683 claims |
| Boehringer IngelheimJardiance | $482 | $96,40591 claims |
| Johnson & JohnsonXarelto | $302 | $77,83370 claims |
| AstraZenecaFarxiga, Brilinta | $213 | $42,25241 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Phoenix
- Paul SorajjaPhoenix$8.8M
- Timothy ByrnePhoenix$2.1M
- Mohamad LazkaniPhoenix$1.1M
- Parminder SinghPhoenix$854K
- Akil LoliPhoenix$506K
- Haidar YassinPhoenix$457K
- Michael WhitePhoenix$417K
- Nezar FallujiPhoenix$348K
- Floyd FortuinPhoenix$263K
- Nishant GuptaPhoenix$196K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.